Retatrutide

Retatrutide is the most advanced metabolic compound in research — a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously.

Retatrutide (development code LY3437943) is a 39-amino acid synthetic peptide developed by Eli Lilly as the first triple-receptor agonist targeting GLP-1R, GIPR, and GCGR in a single molecule. Researchers who buy retatrutide for laboratory studies use it to investigate metabolic pathways involving appetite regulation, energy expenditure, lipolysis, and hepatic fat metabolism

Quality & Testing

Every batch of Retatrutide is manufactured to consistent purity standards and accompanied by a Certificate of Analysis (COA) covering:

• Purity

• Sterility

• Heavy metals

• Endotoxins

• Fentanyl screening

Specifications

• Compound: Retatrutide

• Form: Lyophilized (freeze-dried) powder

• Vial size: 3ML

• Storage: Store lyophilized material frozen and protected from light and moisture; once reconstituted, store refrigerated under appropriate research conditions.

For qualified research use only. Not for human or animal consumption. Information provided is for research documentation purposes only and should not be interpreted as medical advice, treatment guidance, or consumer-use instruction.